CA3216579A1 - Dosage forms and therapeutic uses of l-4-chlorokynurenine - Google Patents

Dosage forms and therapeutic uses of l-4-chlorokynurenine

Info

Publication number
CA3216579A1
CA3216579A1 CA3216579A CA3216579A CA3216579A1 CA 3216579 A1 CA3216579 A1 CA 3216579A1 CA 3216579 A CA3216579 A CA 3216579A CA 3216579 A CA3216579 A CA 3216579A CA 3216579 A1 CA3216579 A1 CA 3216579A1
Authority
CA
Canada
Prior art keywords
chlorokynurenine
administration
pharmaceutical composition
pain
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216579A
Other languages
English (en)
French (fr)
Inventor
H. Ralph Snodgrass
Allen E. Cato
Jack S. Hicklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vistagen Therapeutics Inc
Original Assignee
Vistagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc
Publication of CA3216579A1 publication Critical patent/CA3216579A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
  • Quinoline Compounds (AREA)
CA3216579A 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine Pending CA3216579A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361849191P 2013-01-22 2013-01-22
US61/849,191 2013-01-22
CA3128321A CA3128321C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3128321A Division CA3128321C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Publications (1)

Publication Number Publication Date
CA3216579A1 true CA3216579A1 (en) 2014-07-31

Family

ID=51228003

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3216579A Pending CA3216579A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
CA2898619A Active CA2898619C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
CA3128321A Active CA3128321C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2898619A Active CA2898619C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
CA3128321A Active CA3128321C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Country Status (22)

Country Link
US (8) US9993450B2 (enExample)
EP (4) EP3228313B1 (enExample)
JP (5) JP6436913B2 (enExample)
KR (5) KR20230003410A (enExample)
CN (4) CN113209068A (enExample)
AU (5) AU2014209466B2 (enExample)
BR (1) BR112015017535A2 (enExample)
CA (3) CA3216579A1 (enExample)
CY (1) CY1122403T1 (enExample)
DK (3) DK3598971T3 (enExample)
ES (3) ES2980120T3 (enExample)
HK (1) HK1217170A1 (enExample)
HR (2) HRP20240812T1 (enExample)
HU (1) HUE067381T2 (enExample)
IL (3) IL240090B (enExample)
MX (2) MX375318B (enExample)
PL (2) PL3598971T3 (enExample)
PT (3) PT3228313T (enExample)
RS (1) RS59687B1 (enExample)
SI (2) SI3598971T1 (enExample)
WO (1) WO2014116739A1 (enExample)
ZA (2) ZA201505569B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3216579A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
DK3297619T3 (da) * 2015-05-22 2022-08-15 Vistagen Therapeutics Inc Terapeutiske anvendelser af L-4-chlorkynurenin
WO2017044516A1 (en) * 2015-09-08 2017-03-16 Cephalon, Inc. Prodrugs of chlorokynurenines
CN112236412B (zh) 2018-02-09 2024-01-30 维斯塔津治疗公司 4-氯代犬尿氨酸及中间体的合成
CN109223785A (zh) * 2018-10-29 2019-01-18 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
WO2022082100A1 (en) * 2020-10-16 2022-04-21 Vistagen Therapeutics, Inc. Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5360814A (en) 1991-02-28 1994-11-01 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5484814A (en) * 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
CA2457011C (en) 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
JP2006502158A (ja) 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AU2007235876A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
EP1903028A1 (en) * 2006-09-22 2008-03-26 Werner Tschollar Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
CN102159077A (zh) * 2008-08-21 2011-08-17 吉瑞工厂 用于治疗神经性疼痛的方法
PT2421519T (pt) 2009-04-23 2017-01-26 Univ Zuerich Bloqueadores do recetor nmda para o tratamento de anemia falciforme
RU2012101424A (ru) * 2009-06-17 2013-07-27 Таргасепт, Инк. Устранение l-дофа-индуцированной дискинезии с помощью лигандов нейрональных никотиновых рецепторов
JPWO2011019072A1 (ja) 2009-08-12 2013-01-17 ヒューマン・メタボローム・テクノロジーズ株式会社 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA3216579A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
JP2016513718A (ja) 2013-03-14 2016-05-16 ヴィスタゲン セラピューティクス、インコーポレイテッド キラルキヌレニン化合物及び中間体の合成
US9745342B2 (en) 2013-10-28 2017-08-29 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
DK3297619T3 (da) 2015-05-22 2022-08-15 Vistagen Therapeutics Inc Terapeutiske anvendelser af L-4-chlorkynurenin

Also Published As

Publication number Publication date
PT3228313T (pt) 2019-12-17
JP2016505050A (ja) 2016-02-18
IL240090A0 (en) 2015-09-24
CA3128321C (en) 2023-12-05
AU2018253600A1 (en) 2018-11-22
AU2014209466B2 (en) 2018-11-08
KR102335919B1 (ko) 2021-12-07
DK2948140T3 (en) 2017-08-21
JP2019023195A (ja) 2019-02-14
JP6804497B2 (ja) 2020-12-23
MX375318B (es) 2025-03-06
DK3228313T3 (da) 2019-11-25
IL291831A (en) 2022-06-01
CA2898619A1 (en) 2014-07-31
US20180289649A1 (en) 2018-10-11
CY1122403T1 (el) 2021-01-27
US10632091B2 (en) 2020-04-28
ES2635353T3 (es) 2017-10-03
US9993450B2 (en) 2018-06-12
AU2022221382B2 (en) 2024-09-19
JP2022070894A (ja) 2022-05-13
US20150359772A1 (en) 2015-12-17
US9993453B2 (en) 2018-06-12
US20190125707A1 (en) 2019-05-02
EP2948140B1 (en) 2017-05-10
EP4385563A3 (en) 2024-08-21
PL3598971T3 (pl) 2024-09-09
HK1217170A1 (zh) 2016-12-30
US20180369180A1 (en) 2018-12-27
EP4385563A2 (en) 2024-06-19
SI3598971T1 (sl) 2024-10-30
DK3598971T3 (da) 2024-06-10
ES2751138T3 (es) 2020-03-30
EP3598971A1 (en) 2020-01-29
KR20210063449A (ko) 2021-06-01
US20250161251A1 (en) 2025-05-22
CN113116877A (zh) 2021-07-16
JP7021298B2 (ja) 2022-02-16
US20220409564A1 (en) 2022-12-29
IL276126A (en) 2020-08-31
KR20230003410A (ko) 2023-01-05
MX2020009966A (es) 2020-10-12
CA3128321A1 (en) 2014-07-31
IL240090B (en) 2020-08-31
KR20230098711A (ko) 2023-07-04
ZA201505569B (en) 2017-01-25
MX2015009277A (es) 2015-12-11
CN113209068A (zh) 2021-08-06
IL291831B2 (en) 2026-08-01
US20160158178A1 (en) 2016-06-09
EP3228313B1 (en) 2019-09-11
PT2948140T (pt) 2017-08-10
AU2022221382A1 (en) 2022-09-15
PL3228313T3 (pl) 2020-03-31
US20190133984A1 (en) 2019-05-09
WO2014116739A1 (en) 2014-07-31
KR20210149905A (ko) 2021-12-09
JP2024069257A (ja) 2024-05-21
IL276126B (en) 2022-05-01
HRP20192189T1 (hr) 2020-02-21
ES2980120T3 (es) 2024-09-30
KR102257284B1 (ko) 2021-05-28
PT3598971T (pt) 2024-06-20
CN105073108A (zh) 2015-11-18
JP6436913B2 (ja) 2018-12-12
CN112933073A (zh) 2021-06-11
BR112015017535A2 (pt) 2020-02-04
KR20150109428A (ko) 2015-10-01
US10617663B2 (en) 2020-04-14
AU2018253600B2 (en) 2020-07-09
RS59687B1 (sr) 2020-01-31
CA2898619C (en) 2021-10-19
AU2014209466A1 (en) 2015-08-06
US10980758B2 (en) 2021-04-20
EP2948140A4 (en) 2016-08-03
ZA201607581B (en) 2019-04-24
AU2024278564A1 (en) 2025-01-09
EP3598971B1 (en) 2024-03-20
IL291831B1 (en) 2026-04-01
SI3228313T1 (sl) 2019-12-31
EP2948140A1 (en) 2015-12-02
JP2020183400A (ja) 2020-11-12
HUE067381T2 (hu) 2024-10-28
HRP20240812T1 (hr) 2024-09-27
AU2020204420A1 (en) 2020-07-23
EP3228313A1 (en) 2017-10-11
US12036198B2 (en) 2024-07-16
NZ710121A (en) 2021-01-29

Similar Documents

Publication Publication Date Title
AU2022221382B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40022228A (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40022228B (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40059702A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40056816A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40054519A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
NZ710121B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231016

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241011

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250512

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260116

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260116

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260511